Key Highlights

  • BioNTech traded at US$95.25, against a consensus target of US$123.79.
  • The median target of US$130 implies roughly +36.5% upside from the current price.
  • Targets span US$94 to US$142, framing the range of analyst opinion.
  • The consensus implies +30.0% upside, reflecting the balance of current analyst views.

BioNTech (NASDAQ:BNTX) traded at US$95.25 as of 8 October 2026, against an analyst consensus price target of US$123.79, an implied upside of approximately +30.0%.

What Is the Latest Analyst Price Target?

Provider screener data as at 8 October 2026 shows a mean analyst price target for BioNTech of $123.79 and a median of $130. The lowest target is $94 and the highest is $142. Relative to the $95.25 share price, the mean implies potential upside of 30.0%. The gap between mean and median, at more than $6, indicates a few cautious estimates dragging the average lower. The low target of $94 sits barely 1.3% below the current price, so the share price rests almost at the bottom of the range. The high target of $142 is some 49.1% above the price. A $48 spread is substantial and typical of biotechnology, where outcomes hinge on clinical results.

What Are Analysts Saying?

The provider's consensus rating is Buy. The pattern in the targets indicates considerable conviction that the shares are undervalued, with the median of $130 about 36.5% above the price. For a company without a meaningful Earnings multiple, that conviction presumably rests on the value analysts assign to its research pipeline and cash resources rather than on current profits.

What Could Help the Stock Reach the Price Target?

BioNTech has positioned itself as an immunotherapy company, applying messenger RNA and other platforms to cancer treatments and infectious disease. If analysts prove correct, progress in its oncology programmes could be the principal catalyst. Positive clinical trial data, regulatory approvals and partnerships with larger pharmaceutical groups can each trigger substantial revaluations in the sector. The company has also been regarded as having built a significant financial cushion from its earlier Vaccine success, which could allow it to fund research without relying on external capital, and to pursue acquisitions or collaborations. Continued Demand for respiratory vaccines, even at a lower level than the Pandemic peak, may provide supporting revenue. Should several programmes deliver positive results, the higher end of the target range may come into view.

What Could Prevent the Stock Reaching the Target?

Biotechnology is inherently binary. A failed trial or regulatory setback can erase value quickly, and cancer Drug Development has a high failure rate even for promising science. Revenue from vaccines has declined from its peak, so the company relies on its pipeline to replace it, which raises the stakes for each programme. Competition is fierce from large pharmaceutical groups and numerous biotechnology firms pursuing similar targets, including rival immunotherapy approaches. With no earnings multiple to anchor valuation, the shares may be volatile. The low target of $94 sits just beneath the price, which shows that cautious analysts see little cushion should sentiment turn.

What Should Investors Watch Next?

The next quarterly results and any guidance will show how the vaccine Business is trending and how spending on Research and Development is progressing. More important for the longer term are updates on clinical trials, including data presentations at medical conferences, regulatory filings and decisions, and any new partnerships. Investors may also follow demand for seasonal respiratory vaccines and policy decisions that influence it.

Reading the Gap Between BioNTech's Price and Target

BioNTech (BNTX) was priced at US$95.25 against a consensus target of US$123.79, an implied upside of approximately +30.0%. The median target of US$130 and the range of US$94 to US$142 frame the debate among analysts.